Veza, the Data Security Platform Built on the Power of Authorization, Announces Blackstone as a Customer and Strategic Series C Investor
22.6.2022 19:00:00 EEST | Business Wire | Press release
Veza, the data security platform built on the power of authorization, announced an investment in their Series C funding round from Blackstone Innovations Investments, along with participation from previous investors. To date, Veza has raised a total of $110 million from top-tier investors including Accel, Bain Capital, Ballistic Ventures, GV, Norwest Venture Partners, True Ventures, and others. Blackstone has also selected Veza to help modernize its data security and access governance.
Veza empowers organizations to address today’s greatest cybersecurity challenge: who can and should take what action on what data. As the world increasingly moves online, our changing behaviors are driving a transformational shift toward multi-cloud data systems, apps, computing, and infrastructure. This shift creates a complex, distributed web of human identities, accounts, apps, services, and access points that are constantly changing and susceptible to vulnerabilities. To address this, Veza takes a comprehensive approach that pulls together authorization data from disparate systems, giving customers a single source of truth to manage data access and controls.
“Having a world-class cybersecurity program that protects our brand, reputation, investors and intellectual property is of paramount importance to our firm, and we are continuing to incorporate innovative technology solutions,” says Adam Fletcher, Chief Security Officer at Blackstone. “Our team is always looking for ways to develop a more comprehensive view of access across all of our applications and cloud infrastructure to allow us to modernize the firm’s access controls. We are excited to partner with Veza to help us accomplish this.”
“Blackstone Innovations Investments is committed to investing in cutting-edge technology companies that we believe will have a meaningful impact on Blackstone, our portfolio companies, and the broader industry. We look forward to working with Veza and their impressive leadership team as they enter this next phase of growth,” comments Stevi Petrelli, Head of Blackstone Innovations Investments.
“Institutions across multiple industries view Blackstone as an example of exceptional technology deployment and cybersecurity expertise,” says Tarun Thakur, CEO and Co-Founder of Veza. “Veza has greatly benefited from Blackstone’s product feedback and market insights. We are thrilled to work with Blackstone’s Security team to further modernize data security for their hybrid and multi-cloud environment.”
Additional investment in Veza comes from notable entrepreneurs including Dheeraj Pandey, Co-founder & CEO, DevRev and former CEO, Nutanix, and Lars Dalgaard, Founder Luv Ventures, Founder & Former CEO, SuccessFactors.
“Authorization is the source of truth when it comes to understanding who has access to what,” says Dheeraj Pandey, Co-Founder and CEO of DevRev. “Understanding authorization at scale is one of the hardest problems to address and I am excited to watch team Veza bring on a new era of identity, rooted in authorization. Veza is defining authorization as a standard for protecting data against ransomware and other forms of data breach.”
“Entrepreneurs will tell you that company building is one of the hardest, yet rewarding experiences, with real potential to make an impact,” says Lars Dalgaard, Founder Luv Ventures, Founder & Former CEO SuccessFactors. “When evaluating any company, I look for deep technical breakthrough for a massive market opportunity, deal composition and company traction, and passion amongst founders. And, I’m very excited to be partnering with Tarun and Veza on the mission to build an iconic company that will revolutionize the data security industry for decades to come.”
About Veza
Veza is the data security platform built on the power of authorization. Our platform is purpose-built for hybrid multi-cloud environments to help you use and share your data safely. Veza makes it easy to understand, manage, and control who can and should take what action on what data. We organize authorization metadata across identity providers, data systems, cloud service providers, and applications — all to address the toughest data security challenges of the modern era. Founded in 2020, the company is funded by top-tier investors including Accel, Bain Capital, Ballistic Ventures, Blackstone, GV, Norwest Venture Partners, and True Ventures. To learn more, please visit us at veza.com. Many Fortune 500, Fortune 1000 and smaller organizations use its data security platform for protection against ransomware, modernizing access governance for critical data and apps, and implementing data lake security for Snowflake and other solutions. Follow Veza on LinkedIn or on Twitter @vezainc.
About Blackstone
Blackstone is the world’s largest alternative asset manager. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $915 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, Twitter, and Instagram.
Learn more about Veza:
Get started with Veza Free Trial
Veza for Snowflake Access Governance
Modernize Privileged Access for Data
Explore Veza’s Open Authorization API (OAA) for SaaS applications (GitHub, and more)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005641/en/
Contact information
Media Contacts
Teju Shyamsundar
tshyamsundar@veza.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
